Savara (NASDAQ: SVRA) reported Q1 EPS of ($0.27), $0.01 better than the analyst estimate of ($0.28).

“With the recent clarity around the IMPALA 2 study design, along with the expansion of our pipeline with the Phase 3 Apulmiq development program, 2020 has kicked off with a strong start,” said Rob Neville, Chief Executive Officer, Savara. “We are now working diligently to get these two studies initiated as soon as possible.”

For earnings history and earnings-related data on Savara (SVRA) click here.